Cargando…
Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis
BACKGROUND: To evaluate real-world pharmacologic treatment of mixed dyslipidemia in patients with diabetes mellitus (DM). METHODS: All commercial health plan members in a large US managed care database with complete lipid panel results (HDL-C, LDL-C, TG) between 1/1/2006 and 12/31/2006 were identifi...
Autores principales: | Toth, Peter P, Zarotsky, Victoria, Sullivan, Jane M, Laitinen, Dave |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694778/ https://www.ncbi.nlm.nih.gov/pubmed/19450274 http://dx.doi.org/10.1186/1475-2840-8-26 |
Ejemplares similares
-
Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?
por: Kumar, Ajoy, et al.
Publicado: (2010) -
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
por: Ray, Kausik K., et al.
Publicado: (2019) -
Polymorphisms of lipid metabolism enzyme-coding genes in patients with diabetic dyslipidemia
por: Vardarlı, Aslı Tetik, et al.
Publicado: (2017) -
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan
por: Proudman, David, et al.
Publicado: (2020) -
Dyslipidemia in Pediatric Type 2 Diabetes Mellitus
por: Sunil, Bhuvana, et al.
Publicado: (2020)